SPY314.38-1.80 -0.57%
DIA257.24-3.48 -1.33%
IXIC10,547.75+55.25 0.53%

Arcutis Highlights Enrollment Of Last Patient In Phase 2 Proof Of Concept Trial Evaluating ARQ-154 As Potential Treatment For Seborrheic Dermatitis

Benzinga · -